Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells

A J Drysdale, D Ryan, R G Pertwee, B Platt

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

The phytocannabinoid cannabidiol (CBD) is at the forefront of therapeutic cannabinoid research due to its non-psychotropic properties. Research supports its use in a variety of disorders, yet the cellular mechanisms of its action remain unclear. In this study, the effect of CBD upon Ca2+ homeostasis in hippocampal cells was characterised. CBD (1 mu M) elevated intracellular Ca2+ ([Ca2+](i)) by similar to +45% of basal Ca2+ levels in both glia (77% responders) and neurones (51% responders). Responses to CBD were reduced in high excitability HEPES buffered solution (HBS), but not affected in low excitability/low Ca2+ HBS. CBD responses were also significantly reduced (by 50%) by the universal Ca2+ channel blocker cadmium (50 mu M) and the L-type specific Ca2+ channel blocker nifedipine (20 mu M). Interestingly, intracellular store depletion with thapsigargin (2 mu M) had the most dramatic effect on CBD responses, leading on average to a full block of the response. Elevated CBD-induced [Ca2+](i) responses (> + 100%) were observed in the presence of the CB1 receptor antagonist, AM281 (1 mu M), and the vanilloid receptor antagonist, capsazepine (CPZ, 1 mu M). Overall, our data suggest that CBD modulates hippocampal [Ca2+](i) homeostasis via intracellular Ca2+ stores and L-type VGCC-mediated Ca2+ entry, with tonic cannabinoid and vanilloid receptor signalling being negatively coupled to this pathway. (c) 2005 Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)621-631
Number of pages11
JournalNeuropharmacology
Volume50
Issue number5
Early online date28 Dec 2005
DOIs
Publication statusPublished - Apr 2006

Keywords

  • cannabidiol
  • calcium
  • CB1
  • vanilloid
  • voltage-gated calcium channels
  • intracellular calcium stores
  • IP3 receptors
  • ryanodine receptor
  • CANNABINOID RECEPTOR AGONISTS
  • CLOSED-HEAD INJURY
  • MOUSE VAS-DEFERENS
  • CALCIUM-CHANNELS
  • SYNAPTIC-TRANSMISSION
  • NEUROBLASTOMA-CELLS
  • SELECTIVE LIGANDS
  • INDUCED ARTHRITIS
  • NEURONS
  • RAT

Cite this

Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells. / Drysdale, A J ; Ryan, D ; Pertwee, R G ; Platt, B .

In: Neuropharmacology, Vol. 50, No. 5, 04.2006, p. 621-631.

Research output: Contribution to journalArticle

@article{26662b7d08234e2e9a134cd22b6e2fe9,
title = "Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells",
abstract = "The phytocannabinoid cannabidiol (CBD) is at the forefront of therapeutic cannabinoid research due to its non-psychotropic properties. Research supports its use in a variety of disorders, yet the cellular mechanisms of its action remain unclear. In this study, the effect of CBD upon Ca2+ homeostasis in hippocampal cells was characterised. CBD (1 mu M) elevated intracellular Ca2+ ([Ca2+](i)) by similar to +45{\%} of basal Ca2+ levels in both glia (77{\%} responders) and neurones (51{\%} responders). Responses to CBD were reduced in high excitability HEPES buffered solution (HBS), but not affected in low excitability/low Ca2+ HBS. CBD responses were also significantly reduced (by 50{\%}) by the universal Ca2+ channel blocker cadmium (50 mu M) and the L-type specific Ca2+ channel blocker nifedipine (20 mu M). Interestingly, intracellular store depletion with thapsigargin (2 mu M) had the most dramatic effect on CBD responses, leading on average to a full block of the response. Elevated CBD-induced [Ca2+](i) responses (> + 100{\%}) were observed in the presence of the CB1 receptor antagonist, AM281 (1 mu M), and the vanilloid receptor antagonist, capsazepine (CPZ, 1 mu M). Overall, our data suggest that CBD modulates hippocampal [Ca2+](i) homeostasis via intracellular Ca2+ stores and L-type VGCC-mediated Ca2+ entry, with tonic cannabinoid and vanilloid receptor signalling being negatively coupled to this pathway. (c) 2005 Elsevier Ltd. All rights reserved.",
keywords = "cannabidiol, calcium, CB1, vanilloid, voltage-gated calcium channels, intracellular calcium stores, IP3 receptors, ryanodine receptor, CANNABINOID RECEPTOR AGONISTS, CLOSED-HEAD INJURY, MOUSE VAS-DEFERENS, CALCIUM-CHANNELS, SYNAPTIC-TRANSMISSION, NEUROBLASTOMA-CELLS, SELECTIVE LIGANDS, INDUCED ARTHRITIS, NEURONS, RAT",
author = "Drysdale, {A J} and D Ryan and Pertwee, {R G} and B Platt",
year = "2006",
month = "4",
doi = "10.1016/j.neuropharm.2005.11.008",
language = "English",
volume = "50",
pages = "621--631",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "PERGAMON-ELSEVIER SCIENCE LTD",
number = "5",

}

TY - JOUR

T1 - Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells

AU - Drysdale, A J

AU - Ryan, D

AU - Pertwee, R G

AU - Platt, B

PY - 2006/4

Y1 - 2006/4

N2 - The phytocannabinoid cannabidiol (CBD) is at the forefront of therapeutic cannabinoid research due to its non-psychotropic properties. Research supports its use in a variety of disorders, yet the cellular mechanisms of its action remain unclear. In this study, the effect of CBD upon Ca2+ homeostasis in hippocampal cells was characterised. CBD (1 mu M) elevated intracellular Ca2+ ([Ca2+](i)) by similar to +45% of basal Ca2+ levels in both glia (77% responders) and neurones (51% responders). Responses to CBD were reduced in high excitability HEPES buffered solution (HBS), but not affected in low excitability/low Ca2+ HBS. CBD responses were also significantly reduced (by 50%) by the universal Ca2+ channel blocker cadmium (50 mu M) and the L-type specific Ca2+ channel blocker nifedipine (20 mu M). Interestingly, intracellular store depletion with thapsigargin (2 mu M) had the most dramatic effect on CBD responses, leading on average to a full block of the response. Elevated CBD-induced [Ca2+](i) responses (> + 100%) were observed in the presence of the CB1 receptor antagonist, AM281 (1 mu M), and the vanilloid receptor antagonist, capsazepine (CPZ, 1 mu M). Overall, our data suggest that CBD modulates hippocampal [Ca2+](i) homeostasis via intracellular Ca2+ stores and L-type VGCC-mediated Ca2+ entry, with tonic cannabinoid and vanilloid receptor signalling being negatively coupled to this pathway. (c) 2005 Elsevier Ltd. All rights reserved.

AB - The phytocannabinoid cannabidiol (CBD) is at the forefront of therapeutic cannabinoid research due to its non-psychotropic properties. Research supports its use in a variety of disorders, yet the cellular mechanisms of its action remain unclear. In this study, the effect of CBD upon Ca2+ homeostasis in hippocampal cells was characterised. CBD (1 mu M) elevated intracellular Ca2+ ([Ca2+](i)) by similar to +45% of basal Ca2+ levels in both glia (77% responders) and neurones (51% responders). Responses to CBD were reduced in high excitability HEPES buffered solution (HBS), but not affected in low excitability/low Ca2+ HBS. CBD responses were also significantly reduced (by 50%) by the universal Ca2+ channel blocker cadmium (50 mu M) and the L-type specific Ca2+ channel blocker nifedipine (20 mu M). Interestingly, intracellular store depletion with thapsigargin (2 mu M) had the most dramatic effect on CBD responses, leading on average to a full block of the response. Elevated CBD-induced [Ca2+](i) responses (> + 100%) were observed in the presence of the CB1 receptor antagonist, AM281 (1 mu M), and the vanilloid receptor antagonist, capsazepine (CPZ, 1 mu M). Overall, our data suggest that CBD modulates hippocampal [Ca2+](i) homeostasis via intracellular Ca2+ stores and L-type VGCC-mediated Ca2+ entry, with tonic cannabinoid and vanilloid receptor signalling being negatively coupled to this pathway. (c) 2005 Elsevier Ltd. All rights reserved.

KW - cannabidiol

KW - calcium

KW - CB1

KW - vanilloid

KW - voltage-gated calcium channels

KW - intracellular calcium stores

KW - IP3 receptors

KW - ryanodine receptor

KW - CANNABINOID RECEPTOR AGONISTS

KW - CLOSED-HEAD INJURY

KW - MOUSE VAS-DEFERENS

KW - CALCIUM-CHANNELS

KW - SYNAPTIC-TRANSMISSION

KW - NEUROBLASTOMA-CELLS

KW - SELECTIVE LIGANDS

KW - INDUCED ARTHRITIS

KW - NEURONS

KW - RAT

U2 - 10.1016/j.neuropharm.2005.11.008

DO - 10.1016/j.neuropharm.2005.11.008

M3 - Article

VL - 50

SP - 621

EP - 631

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 5

ER -